Core Viewpoint - The company, Guoshengtang (02273), has announced a share buyback plan authorized by shareholders during the annual general meeting scheduled for June 20, 2025, allowing the purchase of up to 23.6965 million shares, representing 10% of the total issued shares as of that date [1] Summary by Sections - **Share Buyback Authorization** - The board of directors has been granted the authority to repurchase shares up to a maximum of 2369.65 million shares, which constitutes 10% of the total issued shares as of June 20, 2025 [1] - **Implementation of Buyback** - On August 29, 2025, the board resolved to exercise the buyback authorization and will repurchase shares in the open market for a total price of up to 300 million Hong Kong dollars [1] - Additionally, on November 6, 2025, the board decided to further exercise the buyback authorization, allowing for an additional repurchase of shares in the open market for another maximum of 300 million Hong Kong dollars [1]

Core Viewpoint - The company, Gushengtang (02273), has received authorization from shareholders to repurchase up to 23.6965 million shares, representing 10% of the total issued shares as of June 20, 2025 [1] Summary by Relevant Sections - **Share Repurchase Authorization** - The company was granted a general authorization to repurchase shares at the annual general meeting on June 20, 2025 [1] - **Repurchase Plans** - On August 29, 2025, the board resolved to exercise the repurchase authorization, planning to buy back shares in the open market for a total amount of up to 300 million HKD [1] - Additionally, on November 6, 2025, the board decided to further exercise the repurchase authorization, again planning to buy back shares in the open market for another amount of up to 300 million HKD [1]

Core Viewpoint - The company, Gushengtang (02273.HK), has announced a share buyback plan, with a total budget of up to HKD 300 million for the initial buyback and an additional HKD 300 million approved on November 6, 2025, for further buybacks in the open market [1] Group 1 - The board of directors resolved to exercise the buyback authorization on August 29, 2025, allowing the company to repurchase shares in the open market [1] - The total budget for the share buyback has been set at a maximum of HKD 300 million [1] - On November 6, 2025, the board further resolved to increase the buyback authorization by an additional HKD 300 million [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 GUSHENGTANG HOLDINGS LIMITED 固 生 堂 控 股 有 限 公 司 （根據開曼群島法律註冊成立的有限公司） （股份代號：2273） 自願性公告 根據購回授權購回股份 根據股東於2025年6月20日舉行的股東週年大會上通過的股東決議案，本公司 董事（「董事」）獲授購回最多23,696,549股本公司股份（「股份」）的一般授權，佔 截至2025年6月20日已發行股份總數的10%（「購回授權」）。 於2025年8月29日，董事會（「董事會」）決議行使購回授權，適時於公開市場購 回股份，總價最多300百萬港元（「先前建議股份購回」）。除先前建議股份購回 總價，於2025年11月6日，董事會決議進一步行使購回授權，適時於公開市場 購回股份，再次增加最多300百萬港元（「建議股份購回」）。建議股份購回於本 公告日期開始，直至下列最早者：(i)本公司下屆股東週年大會結束時，(ii)任何 適用 ...

固生堂(02273)发布公告，于2025年11月6日，该公司斥资约1376.99万港元购回49.35万股股份，每股回 购价27.74-28.2港元。 ...

Core Viewpoint - The company, Gushengtang (02273), announced a share buyback plan, indicating a strategic move to enhance shareholder value through repurchasing shares at a price range of 27.74 to 28.2 HKD per share [1] Group 1 - The company will spend approximately 13.7699 million HKD to repurchase 493,500 shares [1]

Core Viewpoint - The company, Guoshengtang (02273.HK), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will spend HKD 13.7699 million to repurchase 493,500 shares [1] - The buyback price ranges from HKD 27.74 to HKD 28.20 per share [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 固生堂控股有限公司 呈交日期： 2025年11月6日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02273 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 ...

Core Viewpoint - Company maintains net profit forecasts for 2025-2026 at RMB 4.05 billion and RMB 5.21 billion, with current stock price corresponding to P/E ratios of 14.8 and 11.3 for 2025-2026, respectively, and a target price of HKD 45.8, indicating a potential upside of 62.5% [1] Group 1: Financial Performance - In Q3 2025, the number of patients treated reached approximately 1.607 million, representing a year-on-year growth of 8.2% [2] - The company expects the average selling price (ASP) to stabilize, despite minor impacts from recent healthcare policy changes, with profit margins anticipated to continue improving due to cost optimization efforts [2] Group 2: Strategic Initiatives - The company has partnered with a digital healthcare platform in Singapore to integrate traditional Chinese medicine (TCM) services into Western medical clinics, aiming for a 70% control in the TCM treatment area [3] - The "National Medicine AI Avatar" platform was launched in Singapore, providing a learning platform for TCM practitioners and laying the groundwork for global resource sharing [3] Group 3: Shareholder Returns - From Q1 to Q3 2025, the company repurchased shares worth RMB 141 million and declared a mid-term dividend of RMB 76 million, resulting in a total shareholder return of approximately RMB 217 million, equating to a return rate of 3.2% [4] - With the recent share buyback announcement, the expected shareholder return rate could rise to 5.2%, with a potential annual return rate of around 7% if the dividend distribution remains consistent [4]

Core Viewpoint - Company maintains net profit forecasts for 2025-2026 at RMB 4.05 billion and RMB 5.21 billion, with current stock price corresponding to P/E ratios of 14.8 and 11.3 for those years, respectively. The target price is set at HKD 45.8, indicating a potential upside of 62.5% from the current level [1] Group 1: Financial Performance - In Q3 2025, the number of patients treated reached approximately 1.607 million, reflecting a year-on-year growth of 8.2% [2] - The company expects the average selling price (ASP) to stabilize, despite minor impacts from recent healthcare policy changes. The profit margin is anticipated to continue improving due to cost optimization efforts [2] Group 2: Strategic Initiatives - The company has partnered with a digital healthcare platform in Singapore to integrate traditional Chinese medicine (TCM) services into Western medical clinics, aiming for a 70% control in the TCM treatment area [3] - The "National Medicine AI Avatar" platform was launched in Singapore, providing a learning platform for TCM practitioners and laying the groundwork for global resource sharing [3] Group 3: Shareholder Returns - From Q1 to Q3 2025, the company repurchased shares worth RMB 141 million and declared a mid-term dividend of RMB 76 million, resulting in a total shareholder return of approximately RMB 217 million, equating to a return rate of 3.2% [4] - With the recent share buyback announcement, the expected shareholder return rate could rise to 5.2%, with a potential annual return rate of around 7% if the dividend distribution remains consistent [4]